Fremont, CA, United States of America

Qinhong Ma

This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Medabome, Inc.. Active years: 2022-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qinhong Ma. Retrieved from https://idiyas.com/inventor/qinhong-ma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Revolutionary Innovations by Inventor Qinhong Ma in Cancer Treatment

Introduction: Qinhong Ma, a prominent inventor based in Fremont, CA, has significantly contributed to the field of medical advancements with his innovative approaches to cancer treatment. With a total of two patents to his name, Ma's inventions focus on targeting cancer cells that exhibit specific biomarkers, providing hope for effective therapeutic agents.

Latest Patents: Qinhong Ma's latest patents include the following:

1. **Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment**: This invention offers a therapeutic agent specifically designed for the treatment, prevention, and diagnosis of various cancers associated with cells that overexpress transferrin receptor 1 (TfR1) and its variants. The patent addresses cancers such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoma, breast cancer, and many others. The agent is developed based on unique amino acid sequences of a novel monoclonal antibody (mAb), MAb11-22.1, which shows high specificity for tumor cells, inhibiting the proliferation of multiple human cancer cell lines and growth in xenograft tumor models.

2. **Anti-PODXL antibody MAI1738 and its use for cancer treatment**: This therapeutic agent targets cancers related to cells overexpressing podocalyxin-like protein precursor isoform 2 (PODXL-v2). It addresses various gastric cancers among others. The novel monoclonal antibody (mAb), MAb1738, is based on specialized amino acid sequences that effectively inhibit tumor cell proliferation and can impede the growth and metastasis of gastric cancer in mouse models.

Career Highlights: Qinhong Ma is affiliated with Medabome, Inc., a company poised at the forefront of innovative medical solutions. His work at Medabome highlights his commitment to addressing significant health challenges through groundbreaking technology.

Collaborations: Throughout his career, Qinhong Ma has collaborated with notable colleagues, including Mason Lu and Mary Q Xu, working together to push the boundaries of current cancer therapies and improve patient outcomes.

Conclusion: Qinhong Ma's inventions mark a significant milestone in cancer research and treatment. His dedication to developing targeted therapies exemplifies the innovative spirit in today's medical landscape. As he continues to advance his work, the potential to improve treatment for patients suffering from various cancers remains a focal point of his career.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…